GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon Pharma Indonesia PT (ISX:SCPI) » Definitions » EBITDA

Organon Pharma Indonesia PT (ISX:SCPI) EBITDA : Rp Mil (TTM As of . 20)


View and export this data going back to 1990. Start your Free Trial

What is Organon Pharma Indonesia PT EBITDA?

Organon Pharma Indonesia PT's EBITDA for the three months ended in . 20 was Rp0.00 Mil. Organon Pharma Indonesia PT does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Organon Pharma Indonesia PT's EBITDA per Share for the three months ended in . 20 was Rp0.00. Organon Pharma Indonesia PT does not have enough years/quarters to calculate its EBITDA per Share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Organon Pharma Indonesia PT EBITDA Historical Data

The historical data trend for Organon Pharma Indonesia PT's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Pharma Indonesia PT EBITDA Chart

Organon Pharma Indonesia PT Annual Data
Trend
EBITDA

Organon Pharma Indonesia PT Quarterly Data
EBITDA

Competitive Comparison of Organon Pharma Indonesia PT's EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Organon Pharma Indonesia PT's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organon Pharma Indonesia PT's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon Pharma Indonesia PT's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Organon Pharma Indonesia PT's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Organon Pharma Indonesia PT's EBITDA for the fiscal year that ended in . 20 is calculated as

Organon Pharma Indonesia PT's EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Organon Pharma Indonesia PT  (ISX:SCPI) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Organon Pharma Indonesia PT EBITDA Related Terms

Thank you for viewing the detailed overview of Organon Pharma Indonesia PT's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Organon Pharma Indonesia PT (ISX:SCPI) Business Description

Traded in Other Exchanges
N/A
Address
Jalan Jend Sudirman Kav 21, Sinarmas MSIG Tower, Floor 37 Unit 102 & 106, South Jakarta, IDN, 12920
Organon Pharma Indonesia PT engages in the development, manufacture, and distribution of pharmaceutical products. It operates through manufacturing and commercial segments. Manufacturing, which generates the majority of the revenue, is engaged in pharmaceutical manufacturing.

Organon Pharma Indonesia PT (ISX:SCPI) Headlines

No Headlines